Caris Life Sciences (CAI) Equity Average (2024 - 2026)

Caris Life Sciences' Equity Average history runs 3 years deep, the most recent figure standing at $585.4 million for Q1 2026.

• In Q1 2026, Equity Average rose 122.96% year-over-year to $585.4 million; the TTM figure through Mar 2026 stood at $585.4 million (up 122.96% YoY), while the FY2025 annual figure was -$960.8 million, up 58.62% from the prior year.
• Equity Average was $585.4 million for Q1 2026 at Caris Life Sciences, up from $527.8 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $585.4 million in Q1 2026 to a low of -$2.5 billion in Q1 2025.
• Historically, Equity Average has averaged -$987.9 million across 3 years, with a median of -$1.1 billion in 2025.
• The sharpest annual moves came in 2025 and 2026: Equity Average surged 119.4% in 2025, then surged 122.96% in 2026.
• A 3-year view of Equity Average shows it stood at -$2.5 billion in 2024, then surged by 121.37% to $527.8 million in 2025, then increased by 10.91% to $585.4 million in 2026.
• The last three Equity Average figures came in at $585.4 million (Q1 2026), $527.8 million (Q4 2025), and $465.6 million (Q3 2025), per Business Quant data.